314 related articles for article (PubMed ID: 28597399)
21. Effects of levosimendan versus dobutamine on inflammatory and apoptotic pathways in acutely decompensated chronic heart failure.
Adamopoulos S; Parissis JT; Iliodromitis EK; Paraskevaidis I; Tsiapras D; Farmakis D; Karatzas D; Gheorghiade M; Filippatos GS; Kremastinos DT
Am J Cardiol; 2006 Jul; 98(1):102-6. PubMed ID: 16784930
[TBL] [Abstract][Full Text] [Related]
22. Randomized clinical trials with levosimendan.
Mebazaa A; Barraud D; Welschbillig S
Am J Cardiol; 2005 Sep; 96(6A):74G-9G. PubMed ID: 16181826
[TBL] [Abstract][Full Text] [Related]
23. Levosimendan: a new option in acute cardiac failure.
Holley AD; Ziegenfuss M
Emerg Med Australas; 2006; 18(5-6):505-9. PubMed ID: 17083641
[No Abstract] [Full Text] [Related]
24. Levosimendan: a novel inotropic agent for treatment of acute, decompensated heart failure.
Earl GL; Fitzpatrick JT
Ann Pharmacother; 2005 Nov; 39(11):1888-96. PubMed ID: 16219899
[TBL] [Abstract][Full Text] [Related]
25. [Levosimendan in cardiology and intensive care medicine].
Delle Karth G; Heinz G
Wien Klin Wochenschr; 2004 Jan; 116(1-2):6-14. PubMed ID: 15030117
[TBL] [Abstract][Full Text] [Related]
26. Levosimendan in the treatment of cardiogenic shock.
Buerkem B; Lemm H; Krohe K; Dietz S; Raaz U; Buerke U; Russ M; Schlitt A; Werdan K
Minerva Cardioangiol; 2010 Aug; 58(4):519-30. PubMed ID: 20938415
[TBL] [Abstract][Full Text] [Related]
27. Levosimendan compared with dobutamine in low output patients.
Nieminen MS
Minerva Anestesiol; 2003 Apr; 69(4):258-63. PubMed ID: 12766717
[TBL] [Abstract][Full Text] [Related]
28. [Successful use of levosimendan in a patient with cardiogenic shock complicating acute myocardial infarction].
Mustapha F; Moufida H; Nedia B; Anis L; Iheb L; Habib H
Tunis Med; 2005 Oct; 83(10):635-7. PubMed ID: 16370217
[TBL] [Abstract][Full Text] [Related]
29. Levosimendan.
Figgitt DP; Gillies PS; Goa KL
Drugs; 2001; 61(5):613-27; discussion 628-9. PubMed ID: 11368286
[TBL] [Abstract][Full Text] [Related]
30. Novel biologic mechanisms of levosimendan and its effect on the failing heart.
Parissis JT; Andreadou I; Bistola V; Paraskevaidis I; Filippatos G; Kremastinos DT
Expert Opin Investig Drugs; 2008 Aug; 17(8):1143-50. PubMed ID: 18616411
[TBL] [Abstract][Full Text] [Related]
31. Levosimendan: implications for clinicians.
McBride BF; White CM
J Clin Pharmacol; 2003 Oct; 43(10):1071-81. PubMed ID: 14517189
[TBL] [Abstract][Full Text] [Related]
32. Levosimendan: beyond its simple inotropic effect in heart failure.
Antoniades C; Tousoulis D; Koumallos N; Marinou K; Stefanadis C
Pharmacol Ther; 2007 May; 114(2):184-97. PubMed ID: 17363065
[TBL] [Abstract][Full Text] [Related]
33. Levosimendan for Hemodynamic Support after Cardiac Surgery.
Landoni G; Lomivorotov VV; Alvaro G; Lobreglio R; Pisano A; Guarracino F; Calabrò MG; Grigoryev EV; Likhvantsev VV; Salgado-Filho MF; Bianchi A; Pasyuga VV; Baiocchi M; Pappalardo F; Monaco F; Boboshko VA; Abubakirov MN; Amantea B; Lembo R; Brazzi L; Verniero L; Bertini P; Scandroglio AM; Bove T; Belletti A; Michienzi MG; Shukevich DL; Zabelina TS; Bellomo R; Zangrillo A;
N Engl J Med; 2017 May; 376(21):2021-2031. PubMed ID: 28320259
[TBL] [Abstract][Full Text] [Related]
34. Levosimendan vs dobutamine for patients with acute decompensated heart failure: the SURVIVE Randomized Trial.
Mebazaa A; Nieminen MS; Packer M; Cohen-Solal A; Kleber FX; Pocock SJ; Thakkar R; Padley RJ; Põder P; Kivikko M;
JAMA; 2007 May; 297(17):1883-91. PubMed ID: 17473298
[TBL] [Abstract][Full Text] [Related]
35. Considerations on the efficacy and safety of levosimendan in ischemic heart failure.
Nieminen MS; Sandell EP
Ital Heart J; 2003 May; 4 Suppl 2():39S-44S. PubMed ID: 14635369
[TBL] [Abstract][Full Text] [Related]
36. Evidence-based use of levosimendan in different clinical settings.
De Luca L; Colucci WS; Nieminen MS; Massie BM; Gheorghiade M
Eur Heart J; 2006 Aug; 27(16):1908-20. PubMed ID: 16682381
[TBL] [Abstract][Full Text] [Related]
37. Effects of levosimendan on mortality and hospitalization. A meta-analysis of randomized controlled studies.
Landoni G; Biondi-Zoccai G; Greco M; Greco T; Bignami E; Morelli A; Guarracino F; Zangrillo A
Crit Care Med; 2012 Feb; 40(2):634-46. PubMed ID: 21963578
[TBL] [Abstract][Full Text] [Related]
38. Assessment of sustained effects of levosimendan and dobutamine on left ventricular systolic functions by using novel tissue Doppler derived indices in patients with advanced heart failure.
Oner E; Erturk M; Birant A; Kurtar Mansıroglu A; Akturk IF; Karakurt H; Yalcin AA; Uzun F; Somuncu MU; Yildirim A
Cardiol J; 2015; 22(1):87-93. PubMed ID: 24846511
[TBL] [Abstract][Full Text] [Related]
39. Levosimendan reduces mortality in patients with severe sepsis and septic shock: A meta-analysis of randomized trials.
Zangrillo A; Putzu A; Monaco F; Oriani A; Frau G; De Luca M; Di Tomasso N; Bignami E; Lomivorotov V; Likhvantsev V; Landoni G
J Crit Care; 2015 Oct; 30(5):908-13. PubMed ID: 26093802
[TBL] [Abstract][Full Text] [Related]
40. Levosimendan meta-analyses: Is there a pattern in the effect on mortality?
Pollesello P; Parissis J; Kivikko M; Harjola VP
Int J Cardiol; 2016 Apr; 209():77-83. PubMed ID: 26882190
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
